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SARS-CoV-2 pandemic and COVID-19 diffusion have recently become an international public health emergency. Cancer
patients, as a frail population, are particularly exposed to the risk related to infections. The clinical decision-making
process and the organizational workflow of radiotherapy department should be revised in the light of the critical situation.
We herein provide practical suggestions derived from the available literature and discussed during an online session held
within the e-learning educational program of the European School of Oncology on March 31st 2020.
1. Introduction
At the end of December 2019, in the city of Wuhan Hubei
Province, China, the observation of a cluster of patients
with severe respiratory syndrome lead to discovery of the
SARS-CoV-2 infection, which is presently known to be
responsible for COVID-19 [1]. By mid-February, more
than 60.000 cases were reported in China, and by mid-
March, around 170.000 cases were observed worldwide,
prompting the World Health Organization (WHO) to
label the coronavirus outbreak as a pandemic on March
11th, 2020 [2]. COVID-19 hence became an international
public health emergency. Starting from the early phases of
the outbreak, it has been noted that COVID-19 can be
extremely severe in high-risk patients, including the elderly
population and those with comorbidities. The case fatality
rate for Chinese patients aged between 70 and 79 years was
reported to be 8.0% and 14.8% for those aged ≥80 [3]. In
Italy, one of the most affected countries outside China, the
case fatality rates for the same age categories were reported
as high as 12.8% and 20.2% [4]. Cancer patients, being a
frail population, are particularly exposed to the risk of
COVID-19. Data from Wuhan highlighted a case fatality
rate for cancer patients up to 5.6% compared to 2.1% of the
general population. Moreover, they bear a 5-fold relative risk
of severe respiratory manifestations, requiring invasive
ventilation and finally leading to death [5, 6].
Radiation therapy is a mainstay pillar for cancer treat-
ment as around 50% of cancer patients would require
radiation during the course of their disease [7]. During
standard periods, radiotherapy would be considered as a
“life-saving” procedure, and consequently, efforts should
be placed to ensure its access to all cancer patients [8].
In such a critical situation, as the COVID-19 pandemic
is, and given the fractionated nature of radiotherapy treat-
ments, the risk-benefit ratio may be different and specific
decisions and actions could be taken, particularly in case
of concurrent chemotherapy administration, calling for
shared and interdisciplinary decision-making [9]. Another
point is the burden that the pandemic situation may have
on radiotherapy departments worldwide, with the need to
differently allocate resources, selectively screen the patients
on a daily basis for treatments, deal with a shortage in
workforce, and carefully plan for strategies to properly
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address treatment interruptions or delays [10]. Finally, the
safety of healthcare workers and noninfected patients
should be prioritized. Different contributions have been
recently published, including editorials, perspectives, state-
ments, and recommendations. We herein would like to
wrap up the main findings, inspired by the online session
that was held on March 31st, 2020, within the European
School of Oncology online education platform e-ESO
(http://www.eso.net).
2. Clinical Indications to Radiotherapy
During standard periods, oncologists are supposed to rely
on robust data supported by high-quality evidence in the
therapeutic decision-making process. In such a dramatic
framework, as the COVID-19 pandemic is, different con-
siderations may drive clinical practice, with the possibility
to offer less typical treatment regimens, supported by
lower quality of evidence [11]. Focused attention should be
placed on the proper assessment of the risk-benefit ratio,
balancing the exposure to infection risk with the potential
benefit derived from radiotherapy treatment. For each
patient, the clinical setting should be evaluated together with
the purpose to deliver radiotherapy (definitive/neoadjuvant
vs. adjuvant vs. palliative radiation) [11]. Radiotherapy omis-
sion could be evaluated for
(1) low-risk patients (examples: (a) low-risk luminal A
breast cancer in patients aged ≥65-70 after breast
conservation if undergoing endocrine therapy; (b)
low or favorable intermediate risk prostate cancer
willing to undergo active surveillance
(2) clinical contexts with a predicted small benefit derived
from radiotherapy (examples: (a) glioblastoma in
methylated patients aged >60; (b) unresectable pan-
creatic adenocarcinoma)
(3) palliative settings amenable to systemic options
(uncomplicated metastases, painful metastases
manageable with tailored analgesics) [11]
Whenever radiotherapy is deemed indicated, clinicians
need to consider that “less may be better” and employ
hypofractionated schedules that already have shown nonin-
feriority compared to standard fractionation in well-
designed trials, such as in breast (for whole and partial breast
irradiation and nodal irradiation), prostate (moderate hypo-
fractionation or extreme hypofractionated schedules), and
rectal (short course radiation vs. long-course chemoradia-
tion) cancers and gliomas (moderate hypofractionated
schedules) [12].
3. The Example of Breast Cancer
Breast cancer is a paradigmatic example on how the
radiotherapy decision-making process can be adapted to
this particular situation and a proof of the versatility of
radiation oncology treatment strategies, as pointed out in
the guidelines for breast cancer during the COVID-19
pandemic [13]. Radiotherapy could be safely omitted, after
breast conservation, for low-risk ductal in situ carcinoma
or infiltrative disease with low-risk features (size ≤ 30mm,
node negative, G1-G2, clear resection margins, estrogen
receptor positive, HER2 negative, in patients aged >65
planned to receive hormonal manipulation) [13, 14]. When
whole breast radiotherapy is indicated, 5 fractions can be
used for node-negative patients not requiring a boost
(28-30Gy in once weekly fractions over 5 weeks as per FAST
trial or 26Gy in 5 daily fractions in 1 week as per FAST
Forward trial). Boost dose to the tumor bed should be omit-
ted unless for young patients (≤40 years) and/or for those
having high-risk factors for local recurrence [15]. Nodal
radiotherapy can be omitted for postmenopausal women
after breast conservation in case of 1-2 macrometastases at
sentinel lymph node biopsy and low-risk features
(size ≤ 2 cm, G1-G1, estrogen receptor-positive and HER2-
negative disease) [13].
4. Management of Patients with COVID-19
This is a challenging situation not only in terms of staff
safety but also considering the need to preserve the care
and well-being of other patients within the radiotherapy
department. A hypothetical triage decision tree has been
proposed by colleagues from the United States [10].
For patients having a positive test for SARS-CoV-2
referred for radiotherapy, the first steps should include
(1) the assessment of the adequateness of Personal Pro-
tection Equipment (PPE) for all the personnel
exposed
(2) the confirmation of the appropriate isolation policy
with healthcare authorities, and
(3) the evaluation of the appropriateness of the referral
and the cogency of treatment
If timely initiation of radiotherapy is deemed crucial for
the patient, clinicians should
(1) use PPE in all radiotherapy steps
(2) observe all hospital authorities’ indications
(3) properly sanitize/sterilize or discard all the radio-
therapy equipment in contact with the patient
(4) use the shortest hypofractionated schedules when-
ever reasonable from a clinical perspective
For patients to whom radiotherapy initiation is impor-
tant, but not crucial, clinicians should consider delaying
treatment after the emergency period and, if possible, after
the recommended social-distancing policies are lifted and
use hypofractionation when treating the patient. For
patients whose radiotherapy start can be reasonably
delayed, treating physicians should pursue this policy [10].
For low- or middle-income countries, adequate protec-
tion measures may not be trivial to implement. If so, a
practical decision may be to stop treatment for SARS-
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CoV-2-positive patients and restart the treatment when-
ever possible with adequate compensation for the protrac-
tion in overall treatment time. Specific recommendations
for low- or middle-income countries are urgently needed.
5. Protecting the Staff and Patients
Reducing the risk of infection for both the staff and
patients is crucial. Radiotherapy departments should fol-
low the national directives and the procedures established
by the local authorities for infection control, which should
be proactively involved in the inspection of all the pro-
cesses within the department [11, 16]. As basic principles,
the staff should wash hands before and after contact with
the patient. Patients should also wash their hands or use
alcohol hand rub before entering and leaving the department.
Temperature screening for staff, patients, and visitors is
advisable in compliance with local authorities’ suggestions.
Limiting the access to the radiotherapy department to
patients and necessary caregivers could also be suggested.
A rationalization process to limit patient contact may also
be helpful, creating specific pathways for infected and/or
suspected cases within the department and proactively
minimizing the interaction with staff and other patients
[11, 17]. Restriction of staff movements around the various
sections of the departments is advisable, employing, if possi-
ble, limited functional teams to accomplish the different pro-
fessional tasks. Physical preparation of the department, with
eventual decontamination, should be favored. For patients
with high mucosal or aerosol output, wearing a mask should
be suggested to decrease the risk of contamination [11].
6. A Help from Technology
Technology can be a very helpful tool to enhance suppressive
social distancing, by helping to implement remote working
[11, 18]. All the working typologies that could be exploited
from home, in compliance with local governance and
information technology regulation, should be fostered. As
an example, most of the processes involving the personnel
working in the medical physics department can be
assigned to smart working, including treatment planning,
dosimetry assessment, equipment quality assurance, and
dosimetry check [16]. It means that all electronic charts
and treatment planning data could be accessible remotely
and installed on the personal laptops of the staff members.
Moreover, a proactive adaptation of the available technolo-
gies should be considered by the IT staff of the hospital
including, for example, an increase in the VPN traffic
capability. For academic departments, all the teaching and
training activities could be exploited remotely, using online
platforms and live-streaming sessions [19–21].
7. Conclusion
The global challenges for the healthcare system of the
COVID-19 pandemic have no comparison in recent times.
Unprecedented measures are required to face this critical
situation. Cancer patients are particularly exposed and
may suffer from severe repercussions. The efforts of oncol-
ogy professionals, including those working in the field of
radiation oncology, should be targeted to increase the level
of preparedness of the whole organization, adapt the
decisional process to the current situation, decline the
operational level following the principle of safety and good
clinical sense, communicate and disseminate potentially
useful information, and support staff, patients, and
caregivers [11, 22, 23].
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